Trials / Completed
CompletedNCT00575861
Zileuton and Exhaled Nitric Oxide in Asthmatics
Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Gelb, Arthur F., M.D. · Individual
- Sex
- All
- Age
- 21 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven pathways of inflammation. The addition of zileuton which is a leukotriene synthesis inhibitor by itself or together with inhaled corticosteroids should reduce nitric oxide gas exchange.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | zileuton | zileuton (Zyflo) 600mg qid for 2hr and for 30 days |
Timeline
- Start date
- 2005-09-01
- Completion
- 2007-11-01
- First posted
- 2007-12-18
- Last updated
- 2007-12-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00575861. Inclusion in this directory is not an endorsement.